Kitami, Toshimori, Fukuda, Sanae, Kato, Tamotsu et al. · Scientific reports · 2020 · DOI
Researchers studied 48 ME/CFS patients and 52 healthy people in Japan to find biological markers of the disease. They tested blood samples, gut bacteria, immune cells, and sleep patterns, identifying 26 potential markers that differ between patients and healthy people. Three markers stood out as most important: certain types of white blood cells, gut bacteria composition, and fat-like molecules in the blood, which were especially linked to sleep problems in ME/CFS patients.
This study is significant because ME/CFS currently lacks objective diagnostic tests and approved treatments. By identifying specific molecular patterns in blood and gut bacteria that distinguish ME/CFS patients from healthy people, this research offers hope for developing diagnostic blood tests and understanding disease mechanisms. The finding that sleep disruption correlates with specific metabolic and immune changes may eventually guide treatment strategies.
This study does not establish whether the identified markers cause ME/CFS or result from it—correlation does not prove causation. The findings may not apply to ME/CFS patients outside Japan due to genetic and environmental differences. The study's cross-sectional design cannot determine if these markers appear before symptom onset or how they change over the course of illness.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.